InvestorsHub Logo
Followers 70
Posts 11234
Boards Moderated 0
Alias Born 01/05/2018

Re: None

Tuesday, 09/12/2023 10:44:45 AM

Tuesday, September 12, 2023 10:44:45 AM

Post# of 14944
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News